<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27793" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Progressive Supranuclear Palsy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Agarwal</surname>
            <given-names>Shashank</given-names>
          </name>
          <aff>New York University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gilbert</surname>
            <given-names>Rebecca</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shashank Agarwal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rebecca Gilbert declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>27</day>
          <month>3</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27793.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Progressive supranuclear palsy (PSP) is a form of atypical parkinsonian syndrome, also known as a Parkinson-plus disorder. It is an uncommon neurological disorder that can affect movement, gait, balance, speech, swallowing, vision, eye movements, mood, behavior, and cognition. When the condition was originally referenced in 1964, it was described as a constellation including supranuclear gaze palsy, progressive axial rigidity, pseudobulbar palsy, and mild dementia. Since this condition was originally described, different phenotypes have been characterized and linked to the severity of abnormal tau accumulation and neuronal loss in various brain regions. However, despite variable clinical presentation, neuropathologic features remain consistent among patients with this disease. This activity illustrates the evaluation and treatment of progressive supranuclear palsy and reviews interprofessional teams' role in managing those with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe common presenting signs and symptoms of progressive supranuclear palsy.</p></list-item><list-item><p>Review the conditions that should be ruled out prior to making the diagnosis of progressive supranuclear palsy.</p></list-item><list-item><p>Explain how the diagnosis of progressive supranuclear palsy is made.</p></list-item><list-item><p>Describe a structured interprofessional team approach to provide effective care to and appropriate surveillance for patients with progressive supranuclear palsy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27793&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27793">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27793.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Progressive supranuclear palsy (PSP) is an uncommon neurological disorder that affects movement, gait, balance, speech, swallowing, vision, eye movements, mood, behavior, and cognition. Steele, Richardson, and Olszewski described the syndrome in 1964 as an unusual constellation of supranuclear gaze palsy, progressive axial rigidity, pseudobulbar palsy, and mild dementia.<xref ref-type="bibr" rid="article-27793.r1">[1]</xref>&#x000a0;This disease is now a well-recognized atypical parkinsonian syndrome (or Parkinson-plus disorder).</p>
        <p>In 1972, Steele predicted clinical variants of the syndrome were likely to occur as the disease affected different brainstem nuclei at different times and to different degrees.<xref ref-type="bibr" rid="article-27793.r2">[2]</xref>&#x000a0;Since then, different phenotypes have been characterized and linked to the severity of abnormal tau accumulation and neuronal loss in various brain regions.<xref ref-type="bibr" rid="article-27793.r3">[3]</xref>&#x000a0;Different progressive supranuclear palsies, regardless of clinical characteristics, share similar neuropathologic features.<xref ref-type="bibr" rid="article-27793.r4">[4]</xref></p>
      </sec>
      <sec id="article-27793.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The cause of&#x000a0;progressive&#x000a0;supranuclear palsy&#x000a0;is unknown. Advanced age <xref ref-type="bibr" rid="article-27793.r5">[5]</xref>&#x000a0;and environmental factors such as exposure to toxins are theorized causes.&#x000a0;<xref ref-type="bibr" rid="article-27793.r6">[6]</xref><xref ref-type="bibr" rid="article-27793.r7">[7]</xref>&#x000a0;The tau protein&#x000a0;aggregates may be due to&#x000a0;an unconventional infectious agent,&#x000a0;random genetic mutations, or&#x000a0;some unknown chemical in the food, air, or water which slowly damages certain vulnerable areas of the brain.</p>
      </sec>
      <sec id="article-27793.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Recent studies have reported the prevalence of&#x000a0;progressive&#x000a0;supranuclear palsy&#x000a0;to be 5.8 to 6.5 per 100,000.<xref ref-type="bibr" rid="article-27793.r5">[5]</xref><xref ref-type="bibr" rid="article-27793.r8">[8]</xref><xref ref-type="bibr" rid="article-27793.r9">[9]</xref>&#x000a0;The annual&#x000a0;incidence rate of&#x000a0;progressive&#x000a0;supranuclear palsy&#x000a0;ranged from 0.3 to 0.4 per 100,000 in earlier studies.<xref ref-type="bibr" rid="article-27793.r10">[10]</xref><xref ref-type="bibr" rid="article-27793.r11">[11]</xref><xref ref-type="bibr" rid="article-27793.r12">[12]</xref>. However, a study published in 1999 reported an annual incidence rate of 1.1 per 100,000.<xref ref-type="bibr" rid="article-27793.r13">[13]</xref><xref ref-type="bibr" rid="article-27793.r14">[14]</xref>&#x000a0;The greater incidence found in the latter study is likely due to better case ascertainment with increased recognition of the disorder and its clinical variants.<xref ref-type="bibr" rid="article-27793.r13">[13]</xref>&#x000a0;The annual incidence increases with age from 1.7 cases per 100,000 at ages 50 to 59 years to 14.7 per 100,000 at 80 to 89 years.<xref ref-type="bibr" rid="article-27793.r14">[14]</xref>. The mean age of onset for&#x000a0;progressive&#x000a0;supranuclear palsy&#x000a0;is approximately 65 years <xref ref-type="bibr" rid="article-27793.r15">[15]</xref><xref ref-type="bibr" rid="article-27793.r16">[16]</xref><xref ref-type="bibr" rid="article-27793.r17">[17]</xref>, which is older than in idiopathic Parkinson disease. Virtually no cases of autopsy-confirmed&#x000a0;progressive&#x000a0;supranuclear palsy&#x000a0;have been reported in patients younger than age 40 years.<xref ref-type="bibr" rid="article-27793.r18">[18]</xref>. The original report noted a strong male predominance of approximately 8 to 1.<xref ref-type="bibr" rid="article-27793.r1">[1]</xref>&#x000a0;However, later reports have found no clear gender predominance in&#x000a0;progressive&#x000a0;supranuclear palsy.<xref ref-type="bibr" rid="article-27793.r5">[5]</xref><xref ref-type="bibr" rid="article-27793.r19">[19]</xref><xref ref-type="bibr" rid="article-27793.r20">[20]</xref><xref ref-type="bibr" rid="article-27793.r21">[21]</xref></p>
      </sec>
      <sec id="article-27793.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The defining histopathologic feature of&#x000a0;progressive&#x000a0;supranuclear palsy&#x000a0;is an intracerebral aggregation of the microtubule-associated protein tau with preferential involvement of the subthalamic nucleus, pallidum, striatum, red nucleus, substantia nigra, pontine tegmentum, oculomotor nucleus, medulla, and dentate nucleus.<xref ref-type="bibr" rid="article-27793.r3">[3]</xref>&#x000a0;The aggregates predominantly contain tau isoforms with four microtubule-binding repeats (4R-tau) in neurofibrillary tangles, oligodendrocytic coils, and astrocytic tufts.<xref ref-type="bibr" rid="article-27793.r4">[4]</xref><xref ref-type="bibr" rid="article-27793.r22">[22]</xref><xref ref-type="bibr" rid="article-27793.r23">[23]</xref>&#x000a0;Normally, tau is phosphorylated on a series of serine and threonine residues, regulated by numerous kinases and phosphatases. In&#x000a0;progressive&#x000a0;supranuclear palsy&#x000a0;and other tauopathies, the tau protein is hyperphosphorylated, which causes it to lose its affinity for microtubules and become resistant to proteolysis. This results in the accumulation of tau and the formation of neurofibrillary tangles.<xref ref-type="bibr" rid="article-27793.r24">[24]</xref>&#x000a0;Definite diagnosis of&#x000a0;progressive&#x000a0;supranuclear palsy&#x000a0;currently&#x000a0;requires neuropathological examination.<xref ref-type="bibr" rid="article-27793.r4">[4]</xref><xref ref-type="bibr" rid="article-27793.r25">[25]</xref></p>
        <p>
<bold>Macroscopic Pathology</bold>
</p>
        <p>The gross examination of the brain in&#x000a0;progressive&#x000a0;supranuclear palsy&#x000a0;often shows atrophy of the frontal lobe (especially the precentral gyrus), midbrain (especially the tectum), and to a lesser degree, the pons. The subthalamic nucleus is smaller than expected and maybe discolored gray.<xref ref-type="bibr" rid="article-27793.r25">[25]</xref>&#x000a0;The superior cerebellar peduncle and the hilum of the cerebellar dentate nucleus are usually atrophic and have a gray discoloration due to myelinated fiber loss.</p>
      </sec>
      <sec id="article-27793.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Progressive&#x000a0;supranuclear palsy&#x000a0;is an akinetic-rigid form of parkinsonism. The onset of the disease is insidious and symmetric in most patients. Early in the course of the disease, motor abnormalities are typically axial and not appendicular. Gait difficulty and falls are the most common initial manifestation. Other modes of onset include non-specific dizziness, generalized motor slowing, and personality change. Only occasionally, the onset may be resting tremor.<xref ref-type="bibr" rid="article-27793.r26">[26]</xref>&#x000a0;As the disease progresses, other neurologic manifestations occur, including worsening parkinsonism, dysarthria, dysphagia, frontal cognitive difficulties, and eye movement abnormalities. Although supranuclear ophthalmoplegia is the hallmark of&#x000a0;progressive&#x000a0;supranuclear palsy, some&#x000a0;patients only manifest this late in the progression of the disease. Slowed vertical saccades may be the only eye movement manifestation early on. There are a number of clinical subtypes of&#x000a0;progressive&#x000a0;supranuclear palsy, including classic&#x000a0;progressive&#x000a0;supranuclear palsy-Richardson syndrome (PSP-RS),&#x000a0;progressive&#x000a0;supranuclear palsy-parkinsonism (PSP-P),&#x000a0;progressive&#x000a0;supranuclear palsy-pure akinesia with gait freezing (PSP-PAGF),&#x000a0;progressive&#x000a0;supranuclear palsy-corticobasal syndrome (PSP-CBS),&#x000a0;progressive&#x000a0;supranuclear palsy-behavioral variant of frontotemporal dementia (PSP-bvFTD) and&#x000a0;progressive&#x000a0;supranuclear palsy-progressive non-fluent aphasia (PSP-PNFA).<xref ref-type="bibr" rid="article-27793.r3">[3]</xref></p>
        <p>
<bold>Postural Instability and Falls</bold>
</p>
        <p>Patients with classic&#x000a0;progressive&#x000a0;supranuclear palsy, PSP-RS, have a stiff and broad-based gait, with an inclination to have their knees and trunk extended (as opposed to the flexed posture of idiopathic Parkinson disease), and arms slightly abducted. Instead of turning en bloc, as seen in Parkinson disease, they tend to&#x000a0;pivot quickly, which further increases their risk of falls. This is sometimes referred to as the "drunken sailor gait." When they fall, it is usually backward&#x000a0;due to a lack of postural reflexes.</p>
        <p>
<bold>Oculomotor Findings</bold>
</p>
        <p>Although extraocular movement abnormalities, specifically supranuclear ophthalmoplegia, are the hallmark of&#x000a0;progressive&#x000a0;supranuclear palsy, only a minority of patients present with gaze palsy. Often the first ocular motility abnormality noted on physical examination is impairment of vertical saccades. Eventually, most patients with&#x000a0;progressive&#x000a0;supranuclear palsy&#x000a0;show slow or absent vertical saccades.<xref ref-type="bibr" rid="article-27793.r27">[27]</xref><xref ref-type="bibr" rid="article-27793.r28">[28]</xref>&#x000a0;Typically, downgaze is affected before the upgaze. Horizontal, visually guided saccades&#x000a0;.are also often impaired.<xref ref-type="bibr" rid="article-27793.r29">[29]</xref>&#x000a0;Symptomatic eye movement abnormalities begin at a median of 4 years after disease onset.<xref ref-type="bibr" rid="article-27793.r27">[27]</xref><xref ref-type="bibr" rid="article-27793.r28">[28]</xref><xref ref-type="bibr" rid="article-27793.r27">[27]</xref>&#x000a0;Other oculomotor findings in&#x000a0;progressive&#x000a0;supranuclear palsy&#x000a0;include saccadic intrusions into fixation ("square wave jerks"), loss of optokinetic nystagmus (particularly in the vertical direction), loss of convergence, blepharospasm, and eyelid-opening apraxia. The patient is often unable to suppress the horizontal vestibulo-ocular reflex.<xref ref-type="bibr" rid="article-27793.r28">[28]</xref>&#x000a0;The vestibulo-ocular reflex is present until late in the disease, but with disease progression and brainstem involvement, vestibulo-ocular reflexes may be lost. Eventually, supranuclear gaze palsy may be present in all directions, and toward the end of the disease, the eyes may be virtually immobile.</p>
        <p>The combination of rare blinking, facial dystonia, and gaze abnormalities leads to the development of a classic facial expression of perpetual surprise or astonishment.<xref ref-type="bibr" rid="article-27793.r30">[30]</xref>&#x000a0;Vertical gaze impairment commonly leads to reading problems, spilling food while eating, and contributing to falls while walking.<xref ref-type="bibr" rid="article-27793.r31">[31]</xref></p>
        <p>
<bold>Motor Involvement</bold>
</p>
        <p>Bradykinesia, with marked micrographia, is the primary feature of parkinsonism present in all types of&#x000a0;progressive&#x000a0;supranuclear palsy. Rigidity in patients with&#x000a0;progressive&#x000a0;supranuclear palsy&#x000a0;is usually more apparent in axial than limb muscles, especially the neck and upper trunk. On examination, it can be demonstrated&#x000a0;by resistance to passive movement of the neck.</p>
        <p>There can be dystonia of the neck, typically retrocollis. The face of patients with&#x000a0;progressive&#x000a0;supranuclear palsy&#x000a0;is often stiff, immobile, and deeply furrowed (the look of surprise) also due to dystonia.<xref ref-type="bibr" rid="article-27793.r21">[21]</xref>&#x000a0;About one-third of patients with&#x000a0;progressive&#x000a0;supranuclear palsy&#x000a0;develop pyramidal signs, including hyperreflexia and Babinski signs. A jaw jerk and other frontal release signs can be present. Spastic dysarthria, dysphonia, and dysphagia can be profound in the middle to later stages of the disease.</p>
        <p>
<bold>Cognitive and Behavioral Abnormalities</bold>
</p>
        <p>The neuropsychological profile of&#x000a0;progressive&#x000a0;supranuclear palsy&#x000a0;primarily involves frontal lobe dysfunction. This includes impaired executive function making it difficult to shift between mental tasks,<xref ref-type="bibr" rid="article-27793.r32">[32]</xref>, and spontaneous motor behaviors, such as palilalia, motor perseveration, compulsive spitting, among others.</p>
        <p>The presence of severe frontal cognitive deficits is a common finding in these patients.<xref ref-type="bibr" rid="article-27793.r33">[33]</xref><xref ref-type="bibr" rid="article-27793.r34">[34]</xref><xref ref-type="bibr" rid="article-27793.r35">[35]</xref>&#x000a0;Executive dysfunction may be the presenting symptom of&#x000a0;progressive&#x000a0;supranuclear palsy&#x000a0;in some patients but is more characteristic of the later stages of the disease. Ideomotor apraxia may be a rare manifestation of&#x000a0;progressive&#x000a0;supranuclear palsy, although it is more common and severe in patients with corticobasal degeneration, a syndrome that can overlap clinically with&#x000a0;progressive&#x000a0;supranuclear palsy&#x000a0;<xref ref-type="bibr" rid="article-27793.r36">[36]</xref></p>
        <p>Behavioral abnormalities are also common in patients with&#x000a0;progressive&#x000a0;supranuclear palsy. In a case series of 22 patients with&#x000a0;progressive&#x000a0;supranuclear palsy, the most common behavioral symptoms were apathy (91%), disinhibition (36%), dysphoria (18%), and anxiety (18%).<xref ref-type="bibr" rid="article-27793.r37">[37]</xref>&#x000a0;One study of 188 patients with&#x000a0;progressive&#x000a0;supranuclear palsy&#x000a0;demonstrated depression in 50% and anxiety in 37% <xref ref-type="bibr" rid="article-27793.r38">[38]</xref>, while another study of 74 patients with&#x000a0;progressive&#x000a0;supranuclear palsy&#x000a0;reported obsessive-compulsive symptoms in 24%.<xref ref-type="bibr" rid="article-27793.r39">[39]</xref>&#x000a0;Impulsivity often induces patients to try to&#x000a0;perform motor tasks that&#x000a0;they are not able to do, such as getting up and walking on their own. This can lead to falls.</p>
        <p>Pseudobulbar palsy is another characteristic feature of&#x000a0;progressive&#x000a0;supranuclear palsy. Emotional incontinence is less common than in other forms of pseudobulbar palsy&#x000a0;<xref ref-type="bibr" rid="article-27793.r21">[21]</xref>,&#x000a0;but patients with&#x000a0;progressive&#x000a0;supranuclear palsy&#x000a0;commonly manifest the characteristic hoarse groaning voice along with moaning. Speech perseveration and anomia can be observed.<xref ref-type="bibr" rid="article-27793.r30">[30]</xref></p>
        <p>
<bold>Sleep Disturbances</bold>
</p>
        <p>Early or late insomnia and difficulties in maintaining sleep have all been reported in patients with&#x000a0;progressive&#x000a0;supranuclear palsy. Marked rigidity may result in the inability to remain comfortable in bed, further contributing to sleep complaints. Rapid eye movement sleep behavior disorder (RBD) is infrequently associated with&#x000a0;progressive&#x000a0;supranuclear palsy.<xref ref-type="bibr" rid="article-27793.r40">[40]</xref>&#x000a0;This negative finding, similar to preserved olfaction, can help differentiate progressive&#x000a0;supranuclear palsy, a tauopathy, from Parkinson disease and multiple system atrophy, both of which are synucleinopathies and commonly demonstrate symptoms of RBD.</p>
        <p>Patients with the classic PSP-RS usually develop initial symptoms in their mid-60s, and the disease advances from symptom onset to death in 7 years, on average.<xref ref-type="bibr" rid="article-27793.r41">[41]</xref>&#x000a0;Clinical subtypes of PSP-P and PSP-PAGF&#x000a0;have a more benign course with a survival period of a decade or more.<xref ref-type="bibr" rid="article-27793.r41">[41]</xref>&#x000a0;Both subtypes have an overall&#x000a0;tau&#x000a0;burden less than that of PSP-RS, and the distribution of abnormal tau is relatively limited to the brain stem.<xref ref-type="bibr" rid="article-27793.r42">[42]</xref><xref ref-type="bibr" rid="article-27793.r43">[43]</xref>&#x000a0;The phenotypes of PSP-P and PSP-PAGF can be referred to&#x000a0;as the "brain stem" variants of&#x000a0;progressive&#x000a0;supranuclear palsy, as opposed to the "cortical" variants, which present with predominant cortical features, including PSP-CBS, PSP-bvFTD, and PSP-PNFA.<xref ref-type="bibr" rid="article-27793.r3">[3]</xref></p>
      </sec>
      <sec id="article-27793.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The International Parkinson and Movement Disorder Society (MDS)&#x000a0;progressive&#x000a0;supranuclear palsy&#x000a0;study group published the MDS-PSP criteria in 2017<xref ref-type="bibr" rid="article-27793.r18">[18]</xref>&#x000a0;in appreciation of the spectrum of clinical phenotypes associated with&#x000a0;progressive&#x000a0;supranuclear palsy&#x000a0;pathology. Until the publication of these new criteria, the clinical criteria from the National Institute of Neurological Disorders and Stroke and the Society for PSP (NINDS-SPSP) were the most widely used criteria for in-life&#x000a0;progressive&#x000a0;supranuclear palsy&#x000a0;diagnosis.<xref ref-type="bibr" rid="article-27793.r25">[25]</xref>&#x000a0;The NINDS-SPSP criteria require vertical supranuclear gaze palsy and prominent postural instability with falls in the first year of disease onset for diagnosis of probable&#x000a0;progressive&#x000a0;supranuclear palsy. For possible&#x000a0;progressive&#x000a0;supranuclear palsy, vertical supranuclear gaze palsy or slowed vertical saccades plus postural instability with first-year falls are required. Supportive criteria include proximal more than distal symmetric akinesia or rigidity, abnormal neck posturing (particularly retrocollis), poor levodopa responsiveness, early dysphagia, and/or dysarthria and early onset of specific cognitive-behavioral features.<xref ref-type="bibr" rid="article-27793.r25">[25]</xref>&#x000a0;</p>
        <p>
<bold>Radiographic Features</bold>
</p>
        <p>Neuroimaging in patients with&#x000a0;progressive&#x000a0;supranuclear palsy&#x000a0;by MRI shows atrophy and signal increase in the midbrain, degeneration of the red nucleus, atrophy of the quadrigeminal plate, enlargement of the aqueduct and third ventricle, atrophy of the pons and cerebellum, and signal increase in the inferior olives. With the progression of the disease, frontal and temporal lobe atrophy may develop. While no feature on MRI or functional imaging studies is entirely specific for&#x000a0;progressive&#x000a0;supranuclear palsy, the &#x0201c;hummingbird sign&#x0201d; is often present, in which the shape of the rostral midbrain atrophy on mid-sagittal images looks like a hummingbird (see <bold>Image.</bold> Rostral Midbrain Atrophy in Progressive Supranuclear Palsy).<xref ref-type="bibr" rid="article-27793.r44">[44]</xref>&#x000a0;Midbrain to pons ratio of less than 0.52 using AP diameter measurements was useful in differentiating PSP-RS from MSA. Other&#x000a0;progressive&#x000a0;supranuclear palsy&#x000a0;subtypes were not included in the study.<xref ref-type="bibr" rid="article-27793.r45">[45]</xref>&#x000a0;Fronto-subcortical hypometabolism on fluorodeoxyglucose positron emission tomography (FDG-PET) imaging is also a typical finding in&#x000a0;progressive&#x000a0;supranuclear palsy. Dopamine transporter single-photon emission computed tomography (SPECT) imaging, also known as DaTscan imaging, shows reduced tracer uptake in the striatum. This&#x000a0;is a useful finding to distinguish&#x000a0;progressive&#x000a0;supranuclear palsy&#x000a0;from other mimics such as cerebrovascular disease and normal pressure hydrocephalus.<xref ref-type="bibr" rid="article-27793.r46">[46]</xref>&#x000a0;DaTscan cannot, however, distinguish between Parkinson's disease and&#x000a0;progressive&#x000a0;supranuclear palsy, both of which would show reduced uptake. PET imaging with tau ligand is an encouraging radiologic tool for diagnostic and longitudinal follow-up.<xref ref-type="bibr" rid="article-27793.r47">[47]</xref></p>
      </sec>
      <sec id="article-27793.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The management of the cognitive, motor and gait aspects of&#x000a0;progressive&#x000a0;supranuclear palsy is challenging, and the treatment for individuals suspected to have&#x000a0;progressive&#x000a0;supranuclear palsy&#x000a0;remains symptomatic and supportive, with ongoing clinical trials striving to identify disease-modifying therapies often targeting the underlying tau pathology.&#x000a0;For motor (parkinsonian) symptoms, levodopa combined with a dopa decarboxylase inhibitor (e.g., carbidopa) is generally tried, with typically modest to no success in most&#x000a0;progressive&#x000a0;supranuclear palsy&#x000a0;phenotypes but potential benefit in the PSP-P predominance type. Overall, evidence for mild to moderate benefits with levodopa is low&#x000a0;<xref ref-type="bibr" rid="article-27793.r48">[48]</xref>, but given limited therapeutic options, levodopa is generally tried at doses of up to 1000&#x000a0;mg daily. Other dopaminergic agents are rarely of benefit; amantadine is sometimes tried with limited supportive evidence.<xref ref-type="bibr" rid="article-27793.r48">[48]</xref>&#x000a0;Botulinum toxin injections can be used for focal dystonias, including apraxia of eyelid opening.<xref ref-type="bibr" rid="article-27793.r48">[48]</xref></p>
        <p>The potential value of physical therapy is increasing interest, particularly given evidence of benefit for individuals with Parkinson's disease. A recent trial showed improvement in the Progressive Supranuclear Palsy Rating Scale (PSPRS).<xref ref-type="bibr" rid="article-27793.r49">[49]</xref>&#x000a0;Another study also suggested a potential benefit of the Lee Silverman Voice Treatment (LSVT) in individuals with&#x000a0;progressive&#x000a0;supranuclear palsy, though benefits in&#x000a0;progressive&#x000a0;supranuclear palsy&#x000a0;were less frequently significant than those observed in&#x000a0;Parkinson's disease&#x000a0;patients.<xref ref-type="bibr" rid="article-27793.r50">[50]</xref>&#x000a0;Physical and occupational therapy with particular attention to balance training and &#x0201c;learning to fall&#x0201d; can minimize the potential for injury and provide patients with tools for maneuvering after a fall has occurred. Counseling on food preparation and swallowing to avoid aspiration is indicated in many. The use of a walker is often necessary for safe ambulation and transfers. At late stages, even using a walker is not enough to maintain balance, and patients may need to use a wheelchair exclusively.</p>
        <p>While case reports and series suggest promising experiences with unilateral or bilateral pedunculopontine nucleus (PPN) deep brain stimulation (DBS) in patients with suspected&#x000a0;progressive&#x000a0;supranuclear palsy, a recently published randomized controlled trial of unilateral PPN DBS in 8 individuals with PSP-RS showed no benefit in gait, postural stability, and fall PSPRS subitems when comparing ON and OFF stimulation conditions at 6- and 12-month follow-up.<xref ref-type="bibr" rid="article-27793.r51">[51]</xref>&#x000a0;DBS is&#x000a0;currently&#x000a0;not recommended for&#x000a0;progressive&#x000a0;supranuclear palsy&#x000a0;outside of&#x000a0;research settings.<xref ref-type="bibr" rid="article-27793.r48">[48]</xref></p>
        <p>There are no accepted treatments for the cognitive symptoms in individuals with suspected&#x000a0;progressive&#x000a0;supranuclear palsy, with small trials and case series of cholinesterase inhibitors suggesting that these drugs may help cognition but worsen motor function.<xref ref-type="bibr" rid="article-27793.r48">[48]</xref>&#x000a0;It is critical to address potentially treatable symptoms in&#x000a0;progressive&#x000a0;supranuclear palsy&#x000a0;such as depression, but no&#x000a0;progressive&#x000a0;supranuclear palsy-specific recommendations for such symptomatic management exist.</p>
        <p>To date, studies of potentially disease-modifying therapies have failed to demonstrate efficacy in individuals suspected to have&#x000a0;progressive&#x000a0;supranuclear palsy. Randomized, placebo-controlled trials of riluzole,<xref ref-type="bibr" rid="article-27793.r52">[52]</xref>&#x000a0;davunetide,<xref ref-type="bibr" rid="article-27793.r53">[53]</xref>&#x000a0;tideglusib&#x000a0;<xref ref-type="bibr" rid="article-27793.r54">[54]</xref>, sodium valproate,<xref ref-type="bibr" rid="article-27793.r55">[55]</xref>&#x000a0;and rasagiline<xref ref-type="bibr" rid="article-27793.r56">[56]</xref>&#x000a0;showed no impact on primary endpoints tracking disease progression, though study limitations include sample size (for some studies) and lack of evidence that the agents had the intended effect through theorized mechanisms. Though there have been negative double-blind studies of CoQ10&#x000a0;<xref ref-type="bibr" rid="article-27793.r57">[57]</xref>, there has been a positive double-blind study using the liposomal form&#x000a0;<xref ref-type="bibr" rid="article-27793.r58">[58]</xref></p>
        <p>Regardless of investigational and symptomatic treatment approaches used throughout the disease course, palliative care is an important component of&#x000a0;progressive&#x000a0;supranuclear palsy&#x000a0;treatment with hospice as a valuable resource in the late stages.</p>
        <p>Current investigations of tau-focused&#x000a0;progressive&#x000a0;supranuclear palsy&#x000a0;therapies include TPI-287, a microtubule stabilizer, C2N-8E12/ABBV-8E12, and BMS-986168/BIIB092, both anti-tau monoclonal antibodies, and salsalate, a tau acetylation inhibitor. Microtubule stabilizers are hoped to compensate for microtubule dysfunction associated with loss of tau function; anti-tau monoclonal antibodies are hoped to impede the spread of pathogenic tau, and tau acetylation inhibitors are hoped to inhibit acetylation of soluble tau and thus limit hyperphosphorylation.</p>
      </sec>
      <sec id="article-27793.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of&#x000a0;progressive&#x000a0;supranuclear palsy includes corticobasal ganglionic degeneration (CBGD), <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/viewarticle/26674/">Parkinson diseas</ext-link>e, multiple system atrophy (MSA) of the parkinsonian type, and Pick disease. Microvascular disease of the brain stem and tumors of the midbrain area can mimic progressive&#x000a0;supranuclear palsy.</p>
        <p>Other conditions that may produce similar symptoms include Whipple disease, mitochondrial myopathies, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/viewarticle/31370/">Wilson disease</ext-link>, and adult-onset Niemann-Pick disease. With the bulbar onset of symptoms, myasthenia gravis and amyotrophic lateral sclerosis&#x000a0;should be included in the differential diagnosis.</p>
      </sec>
      <sec id="article-27793.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Disease progression in progressive&#x000a0;supranuclear palsy usually occurs fairly rapidly and relentlessly.<xref ref-type="bibr" rid="article-27793.r57">[57]</xref>&#x000a0;Most patients become dependent on care within 3 or 4 years from presentation. The disorder culminates in death at a median of 6 to 9 years after the diagnosis.<xref ref-type="bibr" rid="article-27793.r59">[59]</xref><xref ref-type="bibr" rid="article-27793.r60">[60]</xref><xref ref-type="bibr" rid="article-27793.r61">[61]</xref>&#x000a0;In addition, quality of life is significantly reduced.<xref ref-type="bibr" rid="article-27793.r62">[62]</xref></p>
        <p>In a 2017 systematic review and meta-analysis, predictors of shorter survival included the progressive&#x000a0;supranuclear palsy-Richardson (PSP-RS) phenotype compared with the progressive&#x000a0;supranuclear palsy-parkinsonism (PSP-P) phenotype, early falls, and early cognitive symptoms (both more common in the PSP-RS phenotype).<xref ref-type="bibr" rid="article-27793.r63">[63]</xref>&#x000a0;Early-onset of dysphagia, which is seen in both the PSP-RS and PSP-P phenotypes, was also predictive of shorter survival. The prognostic effect of the presence of supranuclear gaze palsy was inconsistent across studies. As often seen in the early stages of the PSP-P phenotype, Levodopa response did not predict longer survival.</p>
      </sec>
      <sec id="article-27793.s11" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <list list-type="bullet">
          <list-item>
            <p>Unlike typical Parkinson disease, falls begin within the first year of progressive supranuclear palsy, and by year 3, they are common unless precautions are taken to prevent them.</p>
          </list-item>
          <list-item>
            <p>Downgaze is affected before upgaze, whereas; lateral eye movements are usually&#x000a0;preserved&#x000a0;in progressive&#x000a0;supranuclear palsy.</p>
          </list-item>
          <list-item>
            <p>Apathy seems to predominate over other neurobehavioral abnormalities in progressive supranuclear palsy.</p>
          </list-item>
          <list-item>
            <p>Patients with progressive supranuclear palsy develop frontal cognitive impairment.</p>
          </list-item>
          <list-item>
            <p>The pathology of progressive supranuclear palsy is characterized by widespread neurodegeneration associated with tau protein deposition in subcortical regions.</p>
          </list-item>
          <list-item>
            <p>The first therapeutic step in progressive supranuclear palsy is identifying and prioritizing the symptoms that can be treated.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27793.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>
<bold>Evidence-Based Outcomes</bold>
</p>
        <p>Disease progression in progressive supranuclear palsy usually occurs fairly rapidly and relentlessly.<xref ref-type="bibr" rid="article-27793.r57">[57]</xref>&#x000a0;Most patients become dependent on care within 3 or 4 years from&#x000a0;the presentation. The disorder culminates in death at a median of 6 to 9 years after the diagnosis.<xref ref-type="bibr" rid="article-27793.r59">[59]</xref><xref ref-type="bibr" rid="article-27793.r60">[60]</xref><xref ref-type="bibr" rid="article-27793.r61">[61]</xref>&#x000a0;Quality of life is significantly reduced.<xref ref-type="bibr" rid="article-27793.r62">[62]</xref></p>
        <p>
<bold>An Interprofessional Approach</bold>
</p>
        <p>Given the rapid progression of the disease and rapidly deteriorating quality of life, the education of the patient and family is critical. The home care nurse should closely monitor the patient with particular attention to daily living activities. The pharmacist should pay particular attention to the potential side effects of any medications. Only an integrated systemic care plan can help improve the quality of life and reduce the morbidity of the disease.</p>
        <p>At each clinic visit, the nurse should focus on educating the family and ensuring that all concerns are answered. Today there are support groups for patients with progressive supranuclear palsy that help provide motivation and the latest information.</p>
        <p>It is highly recommended that physical therapy and an occupational therapist be involved early in the disease process in helping maximize function, ambulation and facilitate the use of an ambulatory device.</p>
        <p>Without a cure, the majority of patients are dead within seven years, but with an interprofessional approach, health care workers can make a significant difference in the quality of life.<xref ref-type="bibr" rid="article-27793.r64">[64]</xref> [Level 5]</p>
      </sec>
      <sec id="article-27793.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27793&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27793">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/neurology/progressive-supranuclear-palsy/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=27793">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27793/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27793">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-27793.s14">
        <fig id="article-27793.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Rostral Midbrain Atrophy in Progressive Supranuclear Palsy. The image shows a hummingbird (a) and the midsagittal plain MRI in PSP (b). The region, including the most rostral midbrain, the midbrain tegmentum, the pontine base, and the cerebellum appears to correspond to the bill, crown, body, and wing, respectively, of a hummingbird (Hummingbird sign). Adapted from Kato N, Arai K, Hattori T. Study of the rostral midbrain atrophy in progressive supranuclear palsy. <italic toggle="yes">J Neurol Sci.</italic> 2003;210(1&#x02013;2):57&#x02013;60.&#x000a0;</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Figure__1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-27793.s15">
        <title>References</title>
        <ref id="article-27793.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>STEELE</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>RICHARDSON</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>OLSZEWSKI</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>PROGRESSIVE SUPRANUCLEAR PALSY. A HETEROGENEOUS DEGENERATION INVOLVING THE BRAIN STEM, BASAL GANGLIA AND CEREBELLUM WITH VERTICAL GAZE AND PSEUDOBULBAR PALSY, NUCHAL DYSTONIA AND DEMENTIA.</article-title>
            <source>Arch Neurol</source>
            <year>1964</year>
            <month>Apr</month>
            <volume>10</volume>
            <fpage>333</fpage>
            <page-range>333-59</page-range>
            <pub-id pub-id-type="pmid">14107684</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steele</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Progressive supranuclear palsy.</article-title>
            <source>Brain</source>
            <year>1972</year>
            <volume>95</volume>
            <issue>4</issue>
            <fpage>693</fpage>
            <page-range>693-704</page-range>
            <pub-id pub-id-type="pmid">4647151</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dickson</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Algom</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Tsuboi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Josephs</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Neuropathology of variants of progressive supranuclear palsy.</article-title>
            <source>Curr Opin Neurol</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>394</fpage>
            <page-range>394-400</page-range>
            <pub-id pub-id-type="pmid">20610990</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Litvan</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hauw</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Bartko</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Lantos</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Daniel</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Horoupian</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>McKee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dickson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bancher</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tabaton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jellinger</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders.</article-title>
            <source>J Neuropathol Exp Neurol</source>
            <year>1996</year>
            <month>Jan</month>
            <volume>55</volume>
            <issue>1</issue>
            <fpage>97</fpage>
            <page-range>97-105</page-range>
            <pub-id pub-id-type="pmid">8558176</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Golbe</surname>
                <given-names>LI</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Schoenberg</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Duvoisin</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and natural history of progressive supranuclear palsy.</article-title>
            <source>Neurology</source>
            <year>1988</year>
            <month>Jul</month>
            <volume>38</volume>
            <issue>7</issue>
            <fpage>1031</fpage>
            <page-range>1031-4</page-range>
            <pub-id pub-id-type="pmid">3386818</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Golbe</surname>
                <given-names>LI</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Cody</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Belsh</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Duvoisin</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Grosmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lepore</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Mark</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Sachdeo</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Sage</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Zimmerman</surname>
                <given-names>TR</given-names>
              </name>
            </person-group>
            <article-title>Follow-up study of risk factors in progressive supranuclear palsy.</article-title>
            <source>Neurology</source>
            <year>1996</year>
            <month>Jul</month>
            <volume>47</volume>
            <issue>1</issue>
            <fpage>148</fpage>
            <page-range>148-54</page-range>
            <pub-id pub-id-type="pmid">8710069</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Litvan</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lees</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Rai</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Cambon</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Standaert</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Marras</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Juncos</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Riley</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Reich</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kluger</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bordelon</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shprecher</surname>
                <given-names>DR</given-names>
              </name>
              <collab>for ENGENE-PSP</collab>
            </person-group>
            <article-title>Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study.</article-title>
            <source>Mov Disord</source>
            <year>2016</year>
            <month>May</month>
            <volume>31</volume>
            <issue>5</issue>
            <fpage>644</fpage>
            <page-range>644-52</page-range>
            <pub-id pub-id-type="pmid">26854325</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kawashima</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Miyake</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kusumi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Adachi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nakashima</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of progressive supranuclear palsy in Yonago, Japan.</article-title>
            <source>Mov Disord</source>
            <year>2004</year>
            <month>Oct</month>
            <volume>19</volume>
            <issue>10</issue>
            <fpage>1239</fpage>
            <page-range>1239-40</page-range>
            <pub-id pub-id-type="pmid">15390010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schrag</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ben-Shlomo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Quinn</surname>
                <given-names>NP</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study.</article-title>
            <source>Lancet</source>
            <year>1999</year>
            <month>Nov</month>
            <day>20</day>
            <volume>354</volume>
            <issue>9192</issue>
            <fpage>1771</fpage>
            <page-range>1771-5</page-range>
            <pub-id pub-id-type="pmid">10577638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rajput</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Offord</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Beard</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Kurland</surname>
                <given-names>LT</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of parkinsonism: incidence, classification, and mortality.</article-title>
            <source>Ann Neurol</source>
            <year>1984</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>278</fpage>
            <page-range>278-82</page-range>
            <pub-id pub-id-type="pmid">6333204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Radhakrishnan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Thacker</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Maloo</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Gerryo</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Mousa</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Descriptive epidemiology of some rare neurological diseases in Benghazi, Libya.</article-title>
            <source>Neuroepidemiology</source>
            <year>1988</year>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>159</fpage>
            <page-range>159-64</page-range>
            <pub-id pub-id-type="pmid">3405368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mastaglia</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Grainger</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kee</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sadka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lefroy</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Progressive supranuclear palsy (the Steele-Richardson-Olszewski syndrome) clinical and electrophysiological observations in eleven cases.</article-title>
            <source>Proc Aust Assoc Neurol</source>
            <year>1973</year>
            <volume>10</volume>
            <issue>0</issue>
            <fpage>35</fpage>
            <page-range>35-44</page-range>
            <pub-id pub-id-type="pmid">4792160</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bower</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Maraganore</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>McDonnell</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Rocca</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990.</article-title>
            <source>Neurology</source>
            <year>1997</year>
            <month>Nov</month>
            <volume>49</volume>
            <issue>5</issue>
            <fpage>1284</fpage>
            <page-range>1284-8</page-range>
            <pub-id pub-id-type="pmid">9371909</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wenning</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Litvan</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tolosa</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Milestones in atypical and secondary Parkinsonisms.</article-title>
            <source>Mov Disord</source>
            <year>2011</year>
            <month>May</month>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>1083</fpage>
            <page-range>1083-95</page-range>
            <pub-id pub-id-type="pmid">21626553</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Respondek</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stamelou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kurz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Rajput</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chiu</surname>
                <given-names>WZ</given-names>
              </name>
              <name>
                <surname>van Swieten</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Troakes</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Al Sarraj</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gelpi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gaig</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tolosa</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Oertel</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Giese</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roeber</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Arzberger</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wagenpfeil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>H&#x000f6;glinger</surname>
                <given-names>GU</given-names>
              </name>
              <collab>Movement Disorder Society-endorsed PSP Study Group</collab>
            </person-group>
            <article-title>The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases.</article-title>
            <source>Mov Disord</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>29</volume>
            <issue>14</issue>
            <fpage>1758</fpage>
            <page-range>1758-66</page-range>
            <pub-id pub-id-type="pmid">25370486</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coyle-Gilchrist</surname>
                <given-names>IT</given-names>
              </name>
              <name>
                <surname>Dick</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Patterson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>V&#x000e1;zquez Rodr&#x000ed;quez</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wehmann</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wilcox</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lansdall</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Dawson</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Wiggins</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mead</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brayne</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rowe</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes.</article-title>
            <source>Neurology</source>
            <year>2016</year>
            <month>May</month>
            <day>03</day>
            <volume>86</volume>
            <issue>18</issue>
            <fpage>1736</fpage>
            <page-range>1736-43</page-range>
            <pub-id pub-id-type="pmid">27037234</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Respondek</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kurz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Arzberger</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Compta</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Englund</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Gelpi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Giese</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Irwin</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Meissner</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Nilsson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pantelyat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rajput</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van Swieten</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Troakes</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Josephs</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Mollenhauer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Whitwell</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Antonini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bhatia</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Bordelon</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Corvol</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Colosimo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dodel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kassubek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Krismer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lorenzl</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nestor</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Oertel</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Rabinovici</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Rowe</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>van Eimeren</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wenning</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Boxer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Golbe</surname>
                <given-names>LI</given-names>
              </name>
              <name>
                <surname>Litvan</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Stamelou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>H&#x000f6;glinger</surname>
                <given-names>GU</given-names>
              </name>
              <collab>Movement Disorder Society-Endorsed PSP Study Group</collab>
            </person-group>
            <article-title>Which ante mortem clinical features predict progressive supranuclear palsy pathology?</article-title>
            <source>Mov Disord</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>32</volume>
            <issue>7</issue>
            <fpage>995</fpage>
            <page-range>995-1005</page-range>
            <pub-id pub-id-type="pmid">28500752</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>H&#x000f6;glinger</surname>
                <given-names>GU</given-names>
              </name>
              <name>
                <surname>Respondek</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stamelou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kurz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Josephs</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Mollenhauer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Nilsson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Whitwell</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Arzberger</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Englund</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gelpi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Giese</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Irwin</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Meissner</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Pantelyat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rajput</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van Swieten</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Troakes</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Antonini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bhatia</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Bordelon</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Compta</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Corvol</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Colosimo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dickson</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Dodel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kassubek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Krismer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lorenzl</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Nestor</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Oertel</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Poewe</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Rabinovici</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rowe</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Schellenberg</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Seppi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>van Eimeren</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wenning</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Boxer</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Golbe</surname>
                <given-names>LI</given-names>
              </name>
              <name>
                <surname>Litvan</surname>
                <given-names>I</given-names>
              </name>
              <collab>Movement Disorder Society-endorsed PSP Study Group</collab>
            </person-group>
            <article-title>Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.</article-title>
            <source>Mov Disord</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>32</volume>
            <issue>6</issue>
            <fpage>853</fpage>
            <page-range>853-864</page-range>
            <pub-id pub-id-type="pmid">28467028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santacruz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Uttl</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Litvan</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Grafman</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Progressive supranuclear palsy: a survey of the disease course.</article-title>
            <source>Neurology</source>
            <year>1998</year>
            <month>Jun</month>
            <volume>50</volume>
            <issue>6</issue>
            <fpage>1637</fpage>
            <page-range>1637-47</page-range>
            <pub-id pub-id-type="pmid">9633705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Bruin</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Lees</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Subcortical neurofibrillary degeneration presenting as Steele-Richardson-Olszewski and other related syndromes: a review of 90 pathologically verified cases.</article-title>
            <source>Mov Disord</source>
            <year>1994</year>
            <month>Jul</month>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>381</fpage>
            <page-range>381-9</page-range>
            <pub-id pub-id-type="pmid">7969203</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kristensen</surname>
                <given-names>MO</given-names>
              </name>
            </person-group>
            <article-title>Progressive supranuclear palsy--20 years later.</article-title>
            <source>Acta Neurol Scand</source>
            <year>1985</year>
            <month>Mar</month>
            <volume>71</volume>
            <issue>3</issue>
            <fpage>177</fpage>
            <page-range>177-89</page-range>
            <pub-id pub-id-type="pmid">3993325</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kovacs</surname>
                <given-names>GG</given-names>
              </name>
            </person-group>
            <article-title>Invited review: Neuropathology of tauopathies: principles and practice.</article-title>
            <source>Neuropathol Appl Neurobiol</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-23</page-range>
            <pub-id pub-id-type="pmid">25495175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dickson</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration.</article-title>
            <source>J Neurol</source>
            <year>1999</year>
            <month>Sep</month>
            <volume>246 Suppl 2</volume>
            <fpage>II6</fpage>
            <page-range>II6-15</page-range>
            <pub-id pub-id-type="pmid">10525997</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hauw</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Daniel</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Dickson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Horoupian</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Jellinger</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lantos</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>McKee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tabaton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Litvan</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy).</article-title>
            <source>Neurology</source>
            <year>1994</year>
            <month>Nov</month>
            <volume>44</volume>
            <issue>11</issue>
            <fpage>2015</fpage>
            <page-range>2015-9</page-range>
            <pub-id pub-id-type="pmid">7969952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Litvan</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Agid</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Calne</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dubois</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Duvoisin</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Goetz</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Golbe</surname>
                <given-names>LI</given-names>
              </name>
              <name>
                <surname>Grafman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Growdon</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Hallett</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jankovic</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Quinn</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Tolosa</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zee</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop.</article-title>
            <source>Neurology</source>
            <year>1996</year>
            <month>Jul</month>
            <volume>47</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-9</page-range>
            <pub-id pub-id-type="pmid">8710059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Birdi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rajput</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Fenton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Donat</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Rozdilsky</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Macaulay</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases.</article-title>
            <source>Mov Disord</source>
            <year>2002</year>
            <month>Nov</month>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>1255</fpage>
            <page-range>1255-64</page-range>
            <pub-id pub-id-type="pmid">12465065</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chu</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Reingold</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Cogan</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>The eye movement disorders of progressive supranuclear palsy.</article-title>
            <source>Ophthalmology</source>
            <year>1979</year>
            <month>Mar</month>
            <volume>86</volume>
            <issue>3</issue>
            <fpage>422</fpage>
            <page-range>422-8</page-range>
            <pub-id pub-id-type="pmid">530592</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Riley</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Joshi</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Serra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Otero-Millan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Martinez-Conde</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Strupp</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leigh</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>The disturbance of gaze in progressive supranuclear palsy: implications for pathogenesis.</article-title>
            <source>Front Neurol</source>
            <year>2010</year>
            <volume>1</volume>
            <fpage>147</fpage>
            <pub-id pub-id-type="pmid">21188269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pierrot-Deseilligny</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rivaud</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pillon</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fournier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Agid</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Lateral visually-guided saccades in progressive supranuclear palsy.</article-title>
            <source>Brain</source>
            <year>1989</year>
            <month>Apr</month>
            <volume>112 ( Pt 2)</volume>
            <fpage>471</fpage>
            <page-range>471-87</page-range>
            <pub-id pub-id-type="pmid">2706440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Litvan</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Update on progressive supranuclear palsy.</article-title>
            <source>Curr Neurol Neurosci Rep</source>
            <year>2004</year>
            <month>Jul</month>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>296</fpage>
            <page-range>296-302</page-range>
            <pub-id pub-id-type="pmid">15217544</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boeve</surname>
                <given-names>BF</given-names>
              </name>
            </person-group>
            <article-title>Progressive supranuclear palsy.</article-title>
            <source>Parkinsonism Relat Disord</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>18 Suppl 1</volume>
            <fpage>S192</fpage>
            <page-range>S192-4</page-range>
            <pub-id pub-id-type="pmid">22166432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robbins</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Owen</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Lees</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Leigh</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Marsden</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Quinn</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Summers</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Cognitive deficits in progressive supranuclear palsy, Parkinson's disease, and multiple system atrophy in tests sensitive to frontal lobe dysfunction.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>1994</year>
            <month>Jan</month>
            <volume>57</volume>
            <issue>1</issue>
            <fpage>79</fpage>
            <page-range>79-88</page-range>
            <pub-id pub-id-type="pmid">8301310</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Golbe</surname>
                <given-names>LI</given-names>
              </name>
              <name>
                <surname>Boeve</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Keegan</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Parisi</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>An 81-year-old man with imbalance and memory impairment.</article-title>
            <source>Neurology</source>
            <year>2007</year>
            <month>Apr</month>
            <day>03</day>
            <volume>68</volume>
            <issue>14</issue>
            <fpage>1147</fpage>
            <page-range>1147-52</page-range>
            <pub-id pub-id-type="pmid">17404198</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pillon</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dubois</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lhermitte</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Agid</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Heterogeneity of cognitive impairment in progressive supranuclear palsy, Parkinson's disease, and Alzheimer's disease.</article-title>
            <source>Neurology</source>
            <year>1986</year>
            <month>Sep</month>
            <volume>36</volume>
            <issue>9</issue>
            <fpage>1179</fpage>
            <page-range>1179-85</page-range>
            <pub-id pub-id-type="pmid">3748383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dubois</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pillon</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Legault</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Agid</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lhermitte</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Slowing of cognitive processing in progressive supranuclear palsy. A comparison with Parkinson's disease.</article-title>
            <source>Arch Neurol</source>
            <year>1988</year>
            <month>Nov</month>
            <volume>45</volume>
            <issue>11</issue>
            <fpage>1194</fpage>
            <page-range>1194-9</page-range>
            <pub-id pub-id-type="pmid">3190499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pharr</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Uttl</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Stark</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Litvan</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Fantie</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Grafman</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Comparison of apraxia in corticobasal degeneration and progressive supranuclear palsy.</article-title>
            <source>Neurology</source>
            <year>2001</year>
            <month>Apr</month>
            <day>10</day>
            <volume>56</volume>
            <issue>7</issue>
            <fpage>957</fpage>
            <page-range>957-63</page-range>
            <pub-id pub-id-type="pmid">11294936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Litvan</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mega</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Cummings</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Fairbanks</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Neuropsychiatric aspects of progressive supranuclear palsy.</article-title>
            <source>Neurology</source>
            <year>1996</year>
            <month>Nov</month>
            <volume>47</volume>
            <issue>5</issue>
            <fpage>1184</fpage>
            <page-range>1184-9</page-range>
            <pub-id pub-id-type="pmid">8909427</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schrag</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sheikh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Quinn</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Lees</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Selai</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mathias</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Litvan</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Bower</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Burn</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Low</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jahanshahi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy.</article-title>
            <source>Mov Disord</source>
            <year>2010</year>
            <month>Jun</month>
            <day>15</day>
            <volume>25</volume>
            <issue>8</issue>
            <fpage>1077</fpage>
            <page-range>1077-81</page-range>
            <pub-id pub-id-type="pmid">20535826</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fukui</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hosoda</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Okita</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Obsessive-compulsive behavior as a symptom of dementia in progressive supranuclear palsy.</article-title>
            <source>Dement Geriatr Cogn Disord</source>
            <year>2010</year>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>179</fpage>
            <page-range>179-88</page-range>
            <pub-id pub-id-type="pmid">20798538</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boeve</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Silber</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Parisi</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Dickson</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Ferman</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Benarroch</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Schmeichel</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Ahlskog</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Knopman</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Schenck</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Mahowald</surname>
                <given-names>MW</given-names>
              </name>
            </person-group>
            <article-title>Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism.</article-title>
            <source>Neurology</source>
            <year>2003</year>
            <month>Jul</month>
            <day>08</day>
            <volume>61</volume>
            <issue>1</issue>
            <fpage>40</fpage>
            <page-range>40-5</page-range>
            <pub-id pub-id-type="pmid">12847154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>de Silva</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Paviour</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Pittman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Watt</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Kilford</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Holton</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Revesz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lees</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism.</article-title>
            <source>Brain</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>128</volume>
            <issue>Pt 6</issue>
            <fpage>1247</fpage>
            <page-range>1247-58</page-range>
            <pub-id pub-id-type="pmid">15788542</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Holton</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Strand</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pittman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>de Silva</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lees</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Revesz</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome.</article-title>
            <source>Brain</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>130</volume>
            <issue>Pt 6</issue>
            <fpage>1566</fpage>
            <page-range>1566-76</page-range>
            <pub-id pub-id-type="pmid">17525140</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Holton</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Strand</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Revesz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lees</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy.</article-title>
            <source>Mov Disord</source>
            <year>2007</year>
            <month>Nov</month>
            <day>15</day>
            <volume>22</volume>
            <issue>15</issue>
            <fpage>2235</fpage>
            <page-range>2235-41</page-range>
            <pub-id pub-id-type="pmid">17712855</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kato</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Arai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hattori</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Study of the rostral midbrain atrophy in progressive supranuclear palsy.</article-title>
            <source>J Neurol Sci</source>
            <year>2003</year>
            <month>Jun</month>
            <day>15</day>
            <volume>210</volume>
            <issue>1-2</issue>
            <fpage>57</fpage>
            <page-range>57-60</page-range>
            <pub-id pub-id-type="pmid">12736089</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Massey</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>J&#x000e4;ger</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Paviour</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>O'Sullivan</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Ling</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Kallis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Holton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Revesz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Burn</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Yousry</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lees</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Micallef</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy.</article-title>
            <source>Neurology</source>
            <year>2013</year>
            <month>May</month>
            <day>14</day>
            <volume>80</volume>
            <issue>20</issue>
            <fpage>1856</fpage>
            <page-range>1856-61</page-range>
            <pub-id pub-id-type="pmid">23616165</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>K&#x000e4;gi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bhatia</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Tolosa</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The role of DAT-SPECT in movement disorders.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>81</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <page-range>5-12</page-range>
            <pub-id pub-id-type="pmid">20019219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kepe</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bordelon</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Boxer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thiede</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Mazziotta</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Mendez</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Donoghue</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Small</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Barrio</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>PET imaging of neuropathology in tauopathies: progressive supranuclear palsy.</article-title>
            <source>J Alzheimers Dis</source>
            <year>2013</year>
            <volume>36</volume>
            <issue>1</issue>
            <fpage>145</fpage>
            <page-range>145-53</page-range>
            <pub-id pub-id-type="pmid">23579330</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stamelou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>H&#x000f6;glinger</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>A Review of Treatment Options for Progressive Supranuclear Palsy.</article-title>
            <source>CNS Drugs</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>30</volume>
            <issue>7</issue>
            <fpage>629</fpage>
            <page-range>629-36</page-range>
            <pub-id pub-id-type="pmid">27222018</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Golbe</surname>
                <given-names>LI</given-names>
              </name>
              <name>
                <surname>Ohman-Strickland</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>A clinical rating scale for progressive supranuclear palsy.</article-title>
            <source>Brain</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>130</volume>
            <issue>Pt 6</issue>
            <fpage>1552</fpage>
            <page-range>1552-65</page-range>
            <pub-id pub-id-type="pmid">17405767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sale</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Castiglioni</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>De Pandis</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Torti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dall'armi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Radicati</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Stocchi</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>The Lee Silverman Voice Treatment (LSVT&#x000ae;) speech therapy in progressive supranuclear palsy.</article-title>
            <source>Eur J Phys Rehabil Med</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>51</volume>
            <issue>5</issue>
            <fpage>569</fpage>
            <page-range>569-74</page-range>
            <pub-id pub-id-type="pmid">26138088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scelzo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lozano</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Hamani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Poon</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Aldakheel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zadikoff</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Moro</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Peduncolopontine nucleus stimulation in progressive supranuclear palsy: a randomised trial.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>88</volume>
            <issue>7</issue>
            <fpage>613</fpage>
            <page-range>613-616</page-range>
            <pub-id pub-id-type="pmid">28214797</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bensimon</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ludolph</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Agid</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Vidailhet</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Payan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Leigh</surname>
                <given-names>PN</given-names>
              </name>
              <collab>NNIPPS Study Group</collab>
            </person-group>
            <article-title>Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.</article-title>
            <source>Brain</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>132</volume>
            <issue>Pt 1</issue>
            <fpage>156</fpage>
            <page-range>156-71</page-range>
            <pub-id pub-id-type="pmid">19029129</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boxer</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Knopman</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Doody</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Lees</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Golbe</surname>
                <given-names>LI</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Corvol</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Ludolph</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Burn</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lorenzl</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Litvan</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Roberson</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>H&#x000f6;glinger</surname>
                <given-names>GU</given-names>
              </name>
              <name>
                <surname>Koestler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jack</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Van Deerlin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Randolph</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lobach</surname>
                <given-names>IV</given-names>
              </name>
              <name>
                <surname>Heuer</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Gozes</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Whitaker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hirman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Gold</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morimoto</surname>
                <given-names>BH</given-names>
              </name>
              <collab>AL-108-231 Investigators</collab>
            </person-group>
            <article-title>Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial.</article-title>
            <source>Lancet Neurol</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>13</volume>
            <issue>7</issue>
            <fpage>676</fpage>
            <page-range>676-85</page-range>
            <pub-id pub-id-type="pmid">24873720</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tolosa</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Litvan</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>H&#x000f6;glinger</surname>
                <given-names>GU</given-names>
              </name>
              <name>
                <surname>Burn</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lees</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Andr&#x000e9;s</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez-Carrillo</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Le&#x000f3;n</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Del Ser</surname>
                <given-names>T</given-names>
              </name>
              <collab>TAUROS Investigators</collab>
            </person-group>
            <article-title>A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy.</article-title>
            <source>Mov Disord</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>470</fpage>
            <page-range>470-8</page-range>
            <pub-id pub-id-type="pmid">24532007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leclair-Visonneau</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rouaud</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Debilly</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Durif</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Houeto</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Kreisler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Defebvre</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lamy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Volteau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Dily</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Damier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Boutoleau-Bretonni&#x000e8;re</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lejeune</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Derkinderen</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy.</article-title>
            <source>Clin Neurol Neurosurg</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>146</volume>
            <fpage>35</fpage>
            <page-range>35-9</page-range>
            <pub-id pub-id-type="pmid">27136096</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nuebling</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hensler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zwergal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Crispin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lorenzl</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy.</article-title>
            <source>J Neurol</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>263</volume>
            <issue>8</issue>
            <fpage>1565</fpage>
            <page-range>1565-74</page-range>
            <pub-id pub-id-type="pmid">27230855</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Apetauerova</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Scala</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Hamill</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Pathak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ruthazer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Standaert</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Yacoubian</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>CoQ10 in progressive supranuclear palsy: A randomized, placebo-controlled, double-blind trial.</article-title>
            <source>Neurol Neuroimmunol Neuroinflamm</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>3</volume>
            <issue>5</issue>
            <fpage>e266</fpage>
            <pub-id pub-id-type="pmid">27583276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stamelou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reuss</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pilatus</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Magerkurth</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Niklowitz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Eggert</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Krisp</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Menke</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schade-Brittinger</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Oertel</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>H&#x000f6;glinger</surname>
                <given-names>GU</given-names>
              </name>
            </person-group>
            <article-title>Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial.</article-title>
            <source>Mov Disord</source>
            <year>2008</year>
            <month>May</month>
            <day>15</day>
            <volume>23</volume>
            <issue>7</issue>
            <fpage>942</fpage>
            <page-range>942-949</page-range>
            <pub-id pub-id-type="pmid">18464278</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Sullivan</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Massey</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Silveira-Moriyama</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kempster</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Holton</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Revesz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lees</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Clinical outcomes of progressive supranuclear palsy and multiple system atrophy.</article-title>
            <source>Brain</source>
            <year>2008</year>
            <month>May</month>
            <volume>131</volume>
            <issue>Pt 5</issue>
            <fpage>1362</fpage>
            <page-range>1362-72</page-range>
            <pub-id pub-id-type="pmid">18385183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Testa</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Monza</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ferrarini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Soliveri</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Girotti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Filippini</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Comparison of natural histories of progressive supranuclear palsy and multiple system atrophy.</article-title>
            <source>Neurol Sci</source>
            <year>2001</year>
            <month>Jun</month>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>247</fpage>
            <page-range>247-51</page-range>
            <pub-id pub-id-type="pmid">11731878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>dell'Aquila</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zoccolella</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cardinali</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>de Mari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iliceto</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tartaglione</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lamberti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Logroscino</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Predictors of survival in a series of clinically diagnosed progressive supranuclear palsy patients.</article-title>
            <source>Parkinsonism Relat Disord</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>19</volume>
            <issue>11</issue>
            <fpage>980</fpage>
            <page-range>980-5</page-range>
            <pub-id pub-id-type="pmid">23968651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pekmezovi&#x00107;</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Je&#x0010d;menica-Luki&#x00107;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Petrovi&#x00107;</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>&#x00160;pica</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tomi&#x00107;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kosti&#x00107;</surname>
                <given-names>VS</given-names>
              </name>
            </person-group>
            <article-title>Quality of life in patients with progressive supranuclear palsy: one-year follow-up.</article-title>
            <source>J Neurol</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>262</volume>
            <issue>9</issue>
            <fpage>2042</fpage>
            <page-range>2042-8</page-range>
            <pub-id pub-id-type="pmid">26070289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glasmacher</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Leigh</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Saha</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Predictors of survival in progressive supranuclear palsy and multiple system atrophy: a systematic review and meta-analysis.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2017</year>
            <month>May</month>
            <volume>88</volume>
            <issue>5</issue>
            <fpage>402</fpage>
            <page-range>402-411</page-range>
            <pub-id pub-id-type="pmid">28250027</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27793.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clerici</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ferrazzoli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Maestri</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bossio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zivi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Canesi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pezzoli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Frazzitta</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Rehabilitation in progressive supranuclear palsy: Effectiveness of two multidisciplinary treatments.</article-title>
            <source>PLoS One</source>
            <year>2017</year>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>e0170927</fpage>
            <pub-id pub-id-type="pmid">28158197</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
